<SEC-DOCUMENT>0001564590-19-020048.txt : 20190521
<SEC-HEADER>0001564590-19-020048.hdr.sgml : 20190521
<ACCEPTANCE-DATETIME>20190521170013
ACCESSION NUMBER:		0001564590-19-020048
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20190521
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190521
DATE AS OF CHANGE:		20190521

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IRIDEX CORP
		CENTRAL INDEX KEY:			0001006045
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				770210467
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27598
		FILM NUMBER:		19843083

	BUSINESS ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
		BUSINESS PHONE:		6509404700

	MAIL ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>irix-8k_20190521.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irix-8k_20190521.DOCX.htm
</title>
</head>
<!-- NG Converter v5.0.19114.148 -->
<body>

<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:130.5pt;"></td>
<td style="width:0.9pt;"></td>
<td style="width:24.6pt;"></td>
<td style="width:156pt;"></td>
<td style="width:30pt;"></td>
<td style="width:0.9pt;"></td>
<td style="width:125.1pt;"></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;;font-size:16pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:36pt;;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:16pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8&#8209;K</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:12pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="7" valign="middle" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:11pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION 13 OR 15(d) OF THE<br />SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
<td colspan="4" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">May 21, 2019</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Date of Report (date of earliest event reported)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:22pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX CORPORATION</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0-27598</p></td>
<td colspan="3" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">77-0210467</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of<br />incorporation or organization)</p></td>
<td valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td colspan="3" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification Number)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1212 Terra Bella Avenue<br />Mountain View, California 94043</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code)</p></td>
</tr>
<tr style="height:20.25pt;">
<td colspan="2" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
<td colspan="4" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(650) 940-4700</p></td>
<td valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr style="height:11.65pt;">
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="4" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:8pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr style="height:4.5pt;">
<td colspan="7" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr style="height:11.65pt;">
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:8pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:0.21%;text-indent:-22.3pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Check1"></a><font style="font-size:10pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><a name="Check1"></a>&#9744;</font><font style="font-weight:bold;"></font>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:0.21%;text-indent:-22.3pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9744;</font><font style="font-weight:bold;"></font>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:0.21%;text-indent:-22.3pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Check3"></a><font style="font-size:10pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><a name="Check3"></a>&#9744;</font><font style="font-weight:bold;"></font>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:0.21%;text-indent:-22.3pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9744;</font>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.21%;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.21%;text-indent:0pt;;font-size:10pt;letter-spacing:-0.2pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.21%;text-indent:0pt;;font-size:10pt;letter-spacing:0pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&nbsp;&nbsp;<font style="font-size:11pt;font-family:'Times New Roman';">&#9744;</font><font style="font-size:11pt;"></font></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.21%;text-indent:0pt;;font-size:10pt;letter-spacing:0pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;<font style="font-size:11pt;font-family:'Times New Roman';">&#9744;</font><font style="font-size:11pt;"></font></p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of Class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of Exchange on Which Registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:38%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, par value $0.01 per share</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRIX</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Global Market</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:104.74%;">
<tr>
<td style="width:10.17%;"></td>
<td style="width:94.57%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 5.02.<font style="margin-left:36pt;"></font>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.<font style="font-family:Arial;"> </font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:36pt;">On May 2</font>1, 2019, IRIDEX Corporation <font style="color:#000000;">(the &#8220;Company&#8221;) appointed David I. Bruce to the position of President and Chief Executive Officer effective immediately (the &#8220;Effective Date&#8221;), succeeding William Moore.&nbsp;&nbsp;Mr. Bruce has served as a member of the board of directors of the Company (the &#8220;Board&#8221;) since April 2018.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr.&#160;<font style="color:#000000;">Bruce, 59, previously </font>served as the Chief Operating Officer of Catheter Robotics, Inc., a private company focused on developing and manufacturing remote catheter systems from August&#160;2014 to May&#160;2016.&#160;&#160;From November&#160;2011 to May&#160;2014, Mr.&#160;Bruce served as President, Chief Executive Officer and director of Arstasis, Inc., a private company that manufactures and distributes vascular closure devices for arterial closure in catheterization procedures.&nbsp;&nbsp;Prior to that, Mr. Bruce served&#160;<font style="letter-spacing:-0.05pt;">as CEO of EP MedSystems, a public medical device company specializing in electrophysiology systems and catheters, and led the company to 30% annual growth over two years culminating in its acquisition by St. Jude Medical.&nbsp;&nbsp;</font>Mr.&#160;Bruce holds a B.S. in Mechanical Engineering from the University of California, Berkeley, and an MBA degree from the Wharton School at the University of Pennsylvania<font style="color:#000000;">.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Offer Letter</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this appointment, the Company entered into an offer letter with Mr. Bruce, dated May 17, 2019 and effective as of May 21, 2019, providing for his services as Chief Executive Officer and President of the Company (the &#8220;Offer Letter&#8221;). Pursuant to the Offer Letter, Mr. Bruce will receive a base annual salary of $360,000.&nbsp;&nbsp;In addition to his base salary, the Offer Letter provides Mr. Bruce a target annual bonus opportunity of up to 60% of Mr. Bruce&#8217;s annual base salary, prorated to reflect the portion of the year during which he is employed (the &#8220;Short Term Incentive Bonus&#8221;).&nbsp;&nbsp;The Short Term Incentive Bonus is contingent upon specific corporate and individual management objectives and goals, as determined by the Board.&nbsp;&nbsp;As of May 21, 2019, Mr. Bruce also was granted a one-time award of stock options to purchase 270,000 shares of the Company&#8217;s common stock (the &#8220;Option&#8221;), which will be subject to the terms and conditions of the Company&#8217;s 2008 Equity Incentive Plan (the &#8220;Plan&#8221;), as amended, and standard form of option agreement under the Plan.&nbsp;&nbsp;Mr. Bruce&#8217;s Option shall be scheduled to vest as follows, in each case subject to Mr. Bruce&#8217;s continued service with the Company: 67,500 shares subject to the Option shall vest on the one year anniversary of the Effective Date and 1/48<sup style="font-size:85%; vertical-align:top">th</sup> of the shares subject to the Option shall vest on the same day of the month as the Effective Date (or the last day of the month, if there is no corresponding day in such month).</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, pursuant to the Offer Letter, as of May 21, 2019, Mr.&#160;Bruce was granted a one&#8209;time award of stock options to purchase 400,000 shares of the Company&#8217;s common stock (the &#8220;Additional Option&#8221;) under the Plan and standard form of option agreement under the Plan.&nbsp;&nbsp;The Additional Option shall be eligible to vest based on achievement of specified prices of a share of the Company&#8217;s common stock during the performance period of the Additional Option, which ends December&#160;31, 2023.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Change of Control Severance Agreement with Mr. Bruce</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The offer letter also provides that the Company will enter into a Change in Control Severance Agreement (the &#8220;Change in Control Severance Agreement&#8221;) with Mr. Bruce that provides certain severance benefits in the event that his employment with the Company is terminated under certain circumstances such as: in the event Mr. Bruce is terminated not for cause or he resigns for good reason upon a change in control, he will be entitled to a lump sum cash payment equal to 150% of his annual base salary plus target bonus in effect prior to the change in control, full vesting acceleration of his then-outstanding equity awards, and Company-reimbursed COBRA premiums for a period of up to twelve months following employment termination.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing description of the Offer Letter does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entity by reference to the full text of the Offer Letter, which is filed with this report as Exhibit 10.1 and is incorporated herein by reference.&nbsp;&nbsp;The Change in Control Severance Agreement upon execution by the parties, will be filed separately on a Current Report on Form 8-K or on a Quarterly Report on Form 10-Q.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no family relationships between Mr. Bruce and any director or executive officer of the Company, and other than as described above, no transactions involving Mr. Bruce that would require disclosure under Item 404(a) of Regulation S-K.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">-2</a>-</p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A copy of the Company&#8217;s press release dated May 21, 2019 announcing Mr. Bruce&#8217;s appointment is filed with this report as Exhibit 99.1 and is incorporated by reference herein.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Committee Appointments/Assignments</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 21, 2019, the Board removed Mr. Bruce from its Compensation Committee and its Audit Committee and appointed Scott Shuda to each of those committees.&nbsp;&nbsp;The Board also designated Maria Sainz as Chair of the Compensation Committee and replaced Sanford Fitch with Kenneth Ludlum as Chair of the Audit Committee, effective immediately.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.<font style="font-size:12pt;font-weight:normal;margin-left:36pt;"></font>Financial Statements and Exhibits. </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:100%;">
<tr>
<td style="width:3.7%;"></td>
<td style="width:96.3%;"></td>
</tr>
<tr style="height:8.1pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits </p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.71%;"></td>
<td style="width:6.7%;"></td>
<td style="width:85.6%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="irix-ex101_7.htm"><font style="text-decoration:underline;">Offer Letter between the Company and David I. Bruce.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="irix-ex991_6.htm"><font style="text-decoration:underline;">Press Release dated May 21, 2019.</font></a></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:41.65%;">
<tr>
<td style="width:4.06%;"></td>
<td style="width:1.74%;"></td>
<td style="width:35.85%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX CORPORATION</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David I. Bruce</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David I. Bruce</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 21, 2019 </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">-3</a>-</p></td></tr></table></div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>irix-ex101_7.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irix-ex101_7.htm
</title>
</head>
<!-- NG Converter v5.0.19114.148 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gme2opskb0x4000001.jpg" title="" alt="" style="width:196px;height:59px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 17, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. David Bruce</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21 Udayakavi Lane</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Danville, CA 94525</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">brucedavid@sbcglobal.net</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;Dear Mr. Bruce:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I am very pleased to extend to you this conditional employment offer for the position of <font style="font-weight:bold;">Chief Executive Officer </font>with IRIDEX Corporation.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This conditional offer summarizes several areas related to the terms of the offer:</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Compensation</font>:</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;letter-spacing:0.05pt;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Base Salary: <font style="font-weight:normal;">$13,846.16 payable bi-weekly (annualized to $360,000/yr), in accordance with the Company&#8217;s standard payroll policies, which may be changed from time to time at the discretion of the Company, and subject to applicable withholdings.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bonus Program: <font style="font-weight:normal;">The Executive Bonus Program comprises of two components &#8211; STI (Short Term Incentive) in a form of a cash bonus and LTI (Long Term Incentive) in a form of Stock Options.&nbsp;&nbsp;The following is a summary of the terms of the Executive Bonus Program, and is not intended to and does not change or supersede the Executive MBO Program (&#8220;Bonus Program Plan&#8221;).&nbsp;&nbsp;To the extent this summary is inconsistent or conflicts with the Bonus Program Plan, the terms of the Bonus Program Plan control.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.74%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">STI Bonus:</font>&nbsp;&nbsp;Up to 60% of your annual salary (prorated to date of hire)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.74%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The STI bonus is contingent upon achievement of Management by Objectives (MBO).&nbsp;&nbsp;MBO is an incentive, contingent upon specific corporate and management objectives and goals.&nbsp;&nbsp;Achievement of the bonus will be based upon completion of your MBOs.&nbsp;&nbsp;MBOs will be determined by the Board of Directors in consultation with you.&nbsp;&nbsp;75% of the bonus is tied to the Corporate Goals and 25% of the bonus is tied to your Personal Goal(s).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.74%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Options:<font style="margin-left:36pt;">270,000</font></p>
<p style="margin-top:1pt;line-height:11pt;margin-bottom:0pt;margin-right:0.58%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to your salary and bonus opportunity described above, we will recommend to the Compensation Committee of the Board of Directors at their next meeting that they approve a grant of stock options to purchase 270,000 shares of the Company&#8217;s common stock (the &#8220;Option&#8221;) under the Company&#8217;s 2008&#160;Equity Incentive Plan (&#8220;Plan&#8221;), as amended, and the applicable Option agreement thereunder.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;margin-right:0.58%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon grant, the Option will be scheduled to vest and become exercisable by you over a total period of 48 months following your date of hire (&#8220;Hire Date&#8221;), in the following manner, in each case subject to your continued status as a Service Provider (as defined in the Plan) through each relevant date:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.47%;white-space:nowrap">
<p style="margin-top:7pt;line-height:11pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.47%;white-space:nowrap">
<p style="margin-top:7pt;line-height:11pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:7pt;line-height:11pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="color:#000000;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">12/48 (67,500) of the shares of the Company&#8217;s common stock subject to the Option on the one (1) year anniversary of your Hire Date; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.47%;white-space:nowrap">
<p style="margin-top:7pt;line-height:11pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.47%;white-space:nowrap">
<p style="margin-top:7pt;line-height:11pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:7pt;line-height:11pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-size:12pt;font-family:Times New Roman;">1/48 per month thereafter on the same day of the month as your Hire Date (or the last day of the month, if there is no corresponding day in such month).</font></p></td></tr></table></div>
<p style="margin-top:5pt;line-height:11pt;margin-bottom:0pt;margin-right:0.58%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Per Share Exercise Price: 100% of the fair market value (generally, the closing sales price) of a share of the Company&#8217;s common stock as of the Option&#8217;s grant date. </p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Options:<font style="margin-left:36pt;">400,000</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will also recommend to the Compensation Committee of the Board of Directors at their next meeting that they approve a grant of stock options to purchase 400,000 shares of the Company&#8217;s common stock (the &#8220;Second Option&#8221;) under the Plan and applicable Second Option agreement thereunder.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;color:#000000;">100,000 shares shall vest if the average closing price of the Company&#8217;s common stock during the prior 60 trading days is at least 40% above the 60 trading-day trailing average of IRIX stock as of the day of contract signing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;color:#000000;">100,000 shares shall vest if the average closing price of the Company&#8217;s common stock during the prior 60 trading days is at least $9.00 per share;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;color:#000000;">100,000 shares shall vest if the average closing price of the Company&#8217;s common stock during the prior 60 trading days is at least $12.00 per share;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;color:#000000;">100,000 shall vest if the average closing price of the Company&#8217;s common stock during the prior 60 trading days is at least $18.00 per share.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:6.94%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above performance-based options will expire on&#160;<font style="color:#000000;text-decoration:underline;">12/31/23.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.94%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing is a summary, and is not intended to and does not change or supersede the Plan, option agreement or actual grant, if any, approved by the Compensation Committee.&nbsp;&nbsp;To the extent this summary is inconsistent or conflicts with the Plan, option agreement or grant, the terms of the Plan, option agreement and grant control.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change in Control Severance<font style="font-weight:normal;">:&nbsp;&nbsp;Following your start date you will be eligible to enter into the Company&#8217;s double trigger form of Change in Control Severance Agreement that will provide for full acceleration of all unvested equity grants, cash payment of 1.5 times your salary plus target bonus in effect prior to the change in control, and 12 months COBRA reimbursement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Benefits</font>:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance is available for health, dental, prescriptions, and vision, at a portion of the premium for employee and dependent(s), if they are covered on the IRIDEX plan.&nbsp;&nbsp;The Company also provides for life, business travel, short-term (STD) and long-term disability (LTD) insurance.&nbsp;&nbsp;You may sign up on the 401k Plan effective the first day of any month following your hire date. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a Member of the Executive Staff, you have unvested vacation without accrual or the requirement of tracking time off.&nbsp;&nbsp;You will also accrue two weeks of sick time during your first year of employment.&nbsp;&nbsp;The terms related to your sick leave accrual and usage are set forth in the Iridex Employee Handbook. IRIDEX also compensates their eligible employees for eight holidays and 1-2 floating holidays per year. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Your anticipated start date is May 21, 2019</font><font style="font-weight:normal;">.&nbsp;&nbsp;IRIDEX&#8217;s normal working hours are 8:00 a.m. to 5:00 p.m. Monday through Friday.&nbsp;&nbsp;The Chief Executive Officer position is a salary exempt position and may require you to work beyond the normal work schedule, travel and/or work on Saturdays or Sundays.&nbsp;&nbsp;IRIDEX expects the Chief Executive Officer to work primarily from its headquarters and to be reasonably available in person during normal work hours.&nbsp;&nbsp;IRIDEX has a travel policy that outlines what expenses are appropriate and the documentation which is needed for reimbursement. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This conditional offer of employment will expire at the end of business day on May 21, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please note that this offer of employment is made &#8220;at will&#8221; in which either you or the Company may terminate employment at any time with or without cause.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This offer is contingent upon acceptable results from your background check and also upon your completing, signing, and returning the enclosed:&nbsp;&nbsp;Employment, Confidential Information, Invention Assignment, and Arbitration Agreement; and providing verification of eligibility to work in the United States in accordance with the provisions of the Immigration Reform and Control Act of 1986.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will be required to present evidence of your work eligibility within three days of the first day of employment.&nbsp;&nbsp;A list of sufficient documentation is provided at the end of the I-9 form. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This letter along with the enclosed Confidential Information and Invention Assignment Agreement between you and IRIDEX, set forth the terms of your employment with IRIDEX and supersede any prior negotiations, representations, or agreements, whether oral or written.&nbsp;&nbsp;The provisions of this letter and the Employment, Confidential Information, Invention Assignment, and Arbitration Agreement regarding &#8220;at will&#8221; and arbitration may only be modified by a document signed by you and the Board of Directors that expressly references a change to the at-will employment relationship and/or arbitration agreement.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have very high expectations that your capabilities, experience, and winning attitude will make you an outstanding contributor on the IRIDEX team.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely,</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ruediger Naumann-Etienne, Ph.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lead Independent Director</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:14.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accepted By:</p></td>
<td valign="top"  style="width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;/s/ David I. Bruce</p></td>
<td valign="top"  style="width:15.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:24.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 20, 2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David I. Bruce</p></td>
<td valign="top"  style="width:15.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:24.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>irix-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irix-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.19114.148 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="glr54cjxju5h000001.jpg" title="" alt="" style="width:196px;height:59px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX Announces Leadership Transition; </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">David Bruce Appointed President and CEO</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Mountain View, Calif., <font style="font-weight:normal;">May 21, 2019 (GLOBE NEWSWIRE)&#160;--&#160;IRIDEX Corporation&#160;(NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the appointment of David Bruce to be the company&#8217;s President and Chief Executive Officer, effective today.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are pleased to appoint David Bruce to the role of President and CEO,&#8221; said Dr. Ruediger Naumann-Etienne, Lead Independent Director at IRIDEX.&nbsp;&nbsp;&#8220;David brings substantial experience leading successful commercial and market penetration strategies at several medical device companies, and he has been a member of IRIDEX&#8217;s Board of Directors for over a year.&nbsp;&nbsp;He is well prepared to expand worldwide sales and marketing execution for the Cyclo G6&#174; Glaucoma Laser and Probe System and to build on IRIDEX&#8217;s leading retina laser position in the global market.&nbsp;&nbsp;We look forward to David&#8217;s leadership driving the company to significant growth,&#8221; Naumann-Etienne continued.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Bruce has been a member of IRIDEX&#8217;s board of directors since April, 2018 and has held several CEO and leadership positions in both public and private medical device growth-stage companies.&nbsp;&nbsp;He served as CEO and Director of Arstasis, an arterial access device company, CEO and Director of EP MedSystems, which was acquired by St. Jude Medical, and interim CEO and Director of Patient Safety Technologies.&nbsp;&nbsp;He was also General Manager of the AcuNav Catheter Business for Siemens Medical Solutions, and COO for Catheter Robotics, a privately held, pre-commercial remote catheter systems company.&#160; He holds a MBA from the Wharton School at the University of Pennsylvania and a BS in Mechanical Engineering from the University of California, Berkeley.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;I am excited to lead IRIDEX in capitalizing on our MicroPulse&#174; therapy for glaucoma patients,&#8221; said David Bruce.&nbsp;&nbsp;&#8220;This proven technology, with over 120,000 procedures performed by hundreds of ophthalmologists worldwide and a rapidly-expanding body of clinical data that demonstrate its efficacy, low risk and cost advantages for reduction of intraocular pressures, deserves a much greater role treating the large glaucoma patient population worldwide.&nbsp;&nbsp;Our business model combines proprietary laser systems with disposable delivery probes creating a significant growth and recurring revenue opportunity through broader adoption in the ophthalmology community.&nbsp;&nbsp;Coupling this with IRIDEX&#8217;s leadership position in the retina laser market &#8211; with its own growth opportunities using MicroPulse technology &#8211; creates a platform for the creation of significant shareholder value.&nbsp;&nbsp;I am pleased to join the IRIDEX team to focus on growing the company&#8217;s revenue and achieving our value potential.&#8221;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Naumann-Etienne expressed his appreciation to outgoing CEO, William M. Moore, &#8220;We thank Will for his leadership and contributions over the past six years in IRIDEX&#8217;s development and launch of this novel glaucoma therapy, positioning the company for the exciting growth opportunities ahead.&#8221; </p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About&#160;IRIDEX<font style="font-weight:normal;"><br />IRIDEX Corporation&#160;is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company&#8217;s proprietary MicroPulse&#174; technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX&#8217;s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases.&#160;IRIDEX&#160;products are sold in&#160;the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the&#160;IRIDEX&#160;website at&#160;</font><font style="text-decoration:underline;font-weight:normal;">http://www.iridex.com</font><font style="font-weight:normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Safe Harbor Statement</font><font style="font-weight:normal;"><br />This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the future demand, utilization of the Company's products, plans to introduce new products, plans to increase revenue and growth, build shareholder value and future financial results. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended&#160;December 29, 2018, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the&#160;Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations Contact</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leigh Salvo</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(415) 937-5404</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="RANGE!A1:C41"></a><font style="text-decoration:underline;">investors@iridex.com</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gme2opskb0x4000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gme2opskb0x4000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, /H# 2(  A$! Q$!_\0
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M<G\8_P#DF6I?[\/_ *,6NI\.Q-#X<T]'!#&!6(/8D9_K7+?&/_DF6I?[\/\
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M+*6Y5AAAU[@T >(?'*Y@N/'</D3))Y=DBOL8'!W,<?D17N^D:YI(T*P8ZI9
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M["LV'X;>#H)HYHM!MEDC8.C MP0<@]: .JHHHH$%%%% !1110 4444 %%%%
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M[F34;;R)+@6R2*X8&4\;,COQ6E0 4444 %%8VI>*=)TB^^R7TTD+[48L86V
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MU'9M)J7Q"\.ZG>ZM<Q37N@)<L!(JJ7Z&,#'W6()(ZY)KU@:'I0^UXT^W'VQ
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:_(_XUO111P0I%#&L<:*%5$& H'0 4^@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>glr54cjxju5h000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glr54cjxju5h000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, /H# 2(  A$! Q$!_\0
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M<G\8_P#DF6I?[\/_ *,6NI\.Q-#X<T]'!#&!6(/8D9_K7+?&/_DF6I?[\/\
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M+*6Y5AAAU[@T >(?'*Y@N/'</D3))Y=DBOL8'!W,<?D17N^D:YI(T*P8ZI9
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M["LV'X;>#H)HYHM!MEDC8.C MP0<@]: .JHHHH$%%%% !1110 4444 %%%%
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M[F34;;R)+@6R2*X8&4\;,COQ6E0 4444 %%8VI>*=)TB^^R7TTD+[48L86V
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MU'9M)J7Q"\.ZG>ZM<Q37N@)<L!(JJ7Z&,#'W6()(ZY)KU@:'I0^UXT^W'VQ
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:_(_XUO111P0I%#&L<:*%5$& H'0 4^@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
